Weight-Loss Drugs’ Gains Lift Pharma R&D Returns, but ‘Bubble’ Risk Grows
Deloitte UK and Deloitte US analysis finds projected R&D returns rose for the third straight year — driven largely by GLP‑1...
Read moreDetails